Reducing medication errors: potential benefits of bolus thrombolytic agents.
Open Access
- 1 November 2000
- journal article
- review article
- Published by Wiley in Academic Emergency Medicine
- Vol. 7 (11) , 1285-1289
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trialThe American Journal of Cardiology, 1999
- Overcoming thrombolytic resistanceJACC, 1999
- Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trialAmerican Heart Journal, 1999
- The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study GroupJAMA, 1997
- Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study GroupJAMA, 1995
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Thrombolytic Therapy for Acute Myocardial InfarctionDrugs, 1992
- Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarctionJACC, 1992
- Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activatorJACC, 1989
- Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1989